Drugs / JS010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06158737 | May 2023 → Jun 2024 | migraine disorder | Shanghai Junshi Bioscience Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JS010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06158737 ↗ |
| Route | Subcutaneous | “single subcutaneous injection” NCT06158737 ↗ |